New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|March 4, 2019
Overcoming Resistance to Venetoclax in AML
Author(s)Sangmin Lee, MD
Sangmin Lee, MD, discusses a potential way to overcome resistance to venetoclax in acute myeloid leukemia.
Advertisement
Sangmin Lee, MD, a physician at Weill Cornell Medicine, discusses a potential way to overcome venetoclax (Venclexta) resistance in acute myeloid leukemia (AML).
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
5